At Cancer Therapy Advisor, we recognize that the oncology practitioner is possibly the most specialized professional in medicine, and your approach to patient care is vastly different than that of other specialties.
In addition to utilizing our website for your professional needs, we wanted to provide you with another useful, enduring resource that delivers relevant, up-to-date oncology information. Therefore, we are pleased to announce that the premier print edition of Cancer Therapy Advisor will be mailing today!
If you are familiar with our brand, you may also know our sister publication, Monthly Prescribing Reference (MPR), and you may have even received its quarterly digest-sized Hematology/Oncology edition, which included cancer treatment regimens, drug monographs, and other important oncology news.
The new Cancer Therapy Advisor print edition will replace MPR Hematology/Oncology, and will combine the elements of both resources into one comprehensive oncology publication, which has one main goal: to inform the oncology health care professional.
In Cancer Therapy Advisor, the drug information pulled from the MPR Hematology & Oncology Edition will be organized by cancer type, and some sections of each issue will begin with a detailed treatment regimen from the CTA website.
Other departments from MPR, such as Latest News, New Products, and In the Pipeline, will appear in the front of the new Cancer Therapy Advisor, which will also include content sections you’ll recognize from the CTA website, such as Viewpoints, In the Clinic, as well a CME-accredited feature article.
This print edition is well organized with the most relevant and up-to-date oncology information plus a new journal-size format that allows for the use of larger type, making the content easier to locate and read. The pocket-size format will still be available through the CTA app on your mobile device, while this new “desk-journal” can be placed in your exam room, on your office desk, or in your home.
If you have any feedback on the print edition that you received, please e-mail Nora Ray, Editorial Director at [email protected].